Emerging oral drugs for erectile dysfunction

Expert Opinion on Emerging Drugs

Volumn 9, Issue 1, 2004, Pages 179-189

  Briganti, Alberto ^a   Salonia, Andrea ^a   Suardi, Nazareno ^a   Rigatti, Patrizio ^a   Montorsi, Francesco ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Apomorphine; Drugs; Erectile dysfunction; Sildenafil; Tadalafil; Treatment; Vardenafil

Indexed keywords

AMPRENAVIR; APOMORPHINE; DELAVIRDINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; EFAVIRENZ; INDINAVIR; NELFINAVIR; NITRATE; PROSTAGLANDIN E1; RITONAVIR; SAQUINAVIR; SILDENAFIL; TADALAFIL; UK 103320; VARDENAFIL;

AREA UNDER THE CURVE; BACKACHE; DRUG EFFICACY; DRUG INHIBITION; DRUG MARKETING; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; EUROPE; FLUSHING; HEADACHE; HUMAN; MALE; NAUSEA; PENIS ERECTION; REVIEW; RHINITIS; SEXUAL DYSFUNCTION; SIDE EFFECT;

ADMINISTRATION, ORAL; ADMINISTRATION, SUBLINGUAL; ADULT; AGED; APOMORPHINE; CARBOLINES; COMORBIDITY; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; HUMANS; IMIDAZOLES; IMPOTENCE; MALE; MIDDLE AGED; MULTICENTER STUDIES; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS; SECOND MESSENGER SYSTEMS; SULFONES; TRIAZINES; VASODILATOR AGENTS;

EID: 2642577516     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.9.1.179     Document Type: Review

References (83)

1. JARDIN A, WAGNER G, KHOURI S et al.: Recommendations of the 1st International Consultation on Erectile Dysfunction. In: Erectile Dysfunction. Jardin A, Wagner G, Khouri S, Giuliano F, Padma Nathan H, Rosen R (Eds). Health Publication Ltd, Plymouth, UK (2000):709-726.
2. ARVER S, DOBS AS, MEIKLE AW, ALLEN RP, SANDERS SW, MAZER NA: Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J. Urol. (1996) 155(5):1604-1608.
3. SCHULTEISS D, HILTL DM, MESCHI MR et al.: Pilot study of the transdermal application of testosterone gel to the penile skin for the treatment of hypogonadotropic men with erectile dysfunction. World J. Urol. (2000) 18:431-435.
4. MEULEMAN E, BRODERICK G, MENG TAN H et al.: Clinical evaluation and the doctor-patient dialogue. In: Erectile Dysfunction. Jardin A, Wagner G, Khouri S, Giuliano F, Padma Nathan H, Rosen R (Eds). Health Publication Ltd, Plymouth, UK (2000):115-138.
5. NIH: Consensus Development Panel on Impotence. JAMA (1993) 270:83-90.
6. MONTORSI F, GUAZZONI G, RIGATTI P et al: Pharmacological management of erectile dysfunction. Drugs (1995) 50:465-479.
7. HEATON JP: Central neuropharmacological agents and mechanisms in erectile dysfunction: the role of dopamine. Neuro. Bio. Rev. (2000) 24:507-516.
8. ANDERSSON KE: Pharmacology of erectile function and dysfunction. Urol. Clin. North Am. (2001) 28:233-247. This paper is an excellent review of pathophysiology and molecular targets implicated in erectile function and dysfunction.
9. STIEF CG: Is there a common pathophysiology of erectile dysfunction and how does this relate to new pharmacotherapies? Int. J. Impact. Res. (2002) 14(Suppl. 1):S11-S16.
10. HOLMQUIST F, STIEF CG, JONAS U et al.: Effects of nitric oxide synthase inhibitor NG-nitro-L-arginine on the erectile response to cavernous nerve stimulation in the rabbit. Acta Physiol. Scand. (1991) 143:299-304.
11. TRIGO-ROCHA F, ARONSON WJ, HOHENFELLNER M et al.: Nitric oxide and cGMP: mediators of pelvic nerve-stimulated erection in dogs. Am. J. Physiol. (1993) 264:H419-H422.
12. AZADZOI KM, KIM N, BROWN ML et al.: Endothelium derived nitric oxide and cyclooxygenase products modulate corpus cavernosum smooth muscle tone. J. Urol. (1992) 147:220-225.
13. KUTHE A, WIEDENROTH A, MAGERT HJ et al.: Expression of different phosphodiesterase genes in human cavernous smooth muscle. J. Urol. (2001) 165:280-283. This basic science research elucidates distribution of PDE genes in corpus cavemosum, indicating a role of these enzymes in penile erection regulation.
14. KUTHE A, MAGERT H, UCKERT S et al.: Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis. Eur. Urol. (2000) 38:108-114.
15. ÜCKERT S, KUTHE A, STIEF CG et al.: Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. World J. Urol. (2001) 19:14-22.
16. LIN CS, LAU A, TU R et al.: Expression of three isoforms of cGMP binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. Biochem. Biophys. Res. Commun. (2000) 268:628-635.
17. ANDERSSON KE, HEDLUND P: New directions for erectile dysfunction therapies. Int. J. Impot. Res. (2002) 14(Suppl. 1):S82-S92.
18. GOLDSTEIN I, LUE TF, PADMA-NATHAN H et al.: Oral sildenafil in the treatment of erectile dysfunction. N. Engl. J. Med. (1998) 338:1397-1404.
19. ROSENBERG KP: Sildenafil citrate for SSRI-induced sexual side effects. Am. J. Psychiatry (1999) 156:157.
20. Pfizer, NY, USA, FDA submission: Viagra labelling information. (1997).
21. MUIRHEAD GJ, ALLEN MJ, JAMES GC et al.: Pharmacokinetics of sildenafil (Viagra), a selective cGMP PDE5 inhibitor, after single oral doses in fasted and fed healthy volunteers. Br. J. Clin. Pharmacol (1996) 42:268.
22. WALKER DK, ACKLAND MJ, JAMES GC et al.: Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica (1999) 29:297-310.
23. WARRINGTON JS, SHADER RI, VON MOLTKE LL et al.: In vitro biotrasformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab. Dispos. (2000) 28:392-397.
24. MONTORSI F, MCDERMOTT T, MORGAN R et al.: Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology (1999) 53:1011-1018.
25. KRENZELOK EP: Sildenafil: clinical toxicology profile. J. Toxicol. Clin. Toxicol. (2000) 38:645-651.
26. ASHTON AK, BENNET RG: Sildenafil treatment of serotonin reuptake inhibitor-induced sexual dysfunction. J. Clin. Psychiatry (1999) 60:194-195.
27. NURNBERG HG, LAURIELLO J, HENSLEY PL et al.: Sildenafil for iatrogenic serotoninergic antidepressant medication-induced sexual dysfunction in 4 patients. J. Clin. Psychiatry (1999) 60:33-35.
28. ROSENBERG KP: Sildenafil citrate for SSRI-induced sexual side effects. Am. J. Psychiatry (1999) 156:157.
29. NANDWANI R, GOURLAY Y: Possible interaction between sildenafil and HIV combination therapy. Lancet (1999) 353:840.
30. MUIRHEAD GJ, WULFF MB, FIELDING A et al.: Pharmacokinetic interaction between sildenafil and saquinavir/ritonavir. Br. J. Clin. Pharmacol. (2000) 50:99-107.
31. MILLIGAN PA, MARSHALL SF, KARLSSON MO: A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. Br. J. Clin. Pharmacol. (2002) 53:S45-S52.
32. BOOLELL M, ALLEN MJ, BALLARD SA et al.: Sildenafil: an orally active Type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impot. Res. (1996) 8:47-52.
33. GUAY AT, PEREZ JB, JACOBSON J et al.: Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J. Androl. (2001) 22:793-797.
34. CONTI CR, PEPINE CJ, SWEENEY M: Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am. J. Cardiol. (1999) 83:C29-C34.
35. MORALES A, GINGELL C, COLLINS M et al.: Clinical safety of sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int. J. Impot. Res. (1998) 10:69-73.
36. WALLIS RM, CORBIN JD, FRANCIS SH et al.: Tissue distribution of phosphodiesterase families and effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am. J. Cardiol. (1999) 83(Suppl. 5A):3C-12C.
37. LINA S: On behalf of the Mexico and Brazil Sildenafil Study Group: efficacy and safety of oral Viagra® (sildenafil citrate) for the treatment of erectile dysfunction in Latin America. Congreso del la Confederacion Americana de Urologia, Bueno Aires, Argentina (2000).
38. LEVINSON I, KHALAF I, MAHMOUD KZ: Efficacy of Viagra® (sildenafil citrate) in men with erectile dysfunction in two African Countries. 98th Annual Meeting of New York Section of the American Urological Association, Cape Town, South Africa (2000).
39. TAN HM, CHANG MOH CL, MENDOZA JB et al.: For the ASSESS-1 Study Group. Asian sildenafil efficacy and safety study (ASSESS-1): a double-blind, placebo-controlled, flexible-dose study of oral sildenafil in Malaysian, Singaporean, and Filipino men with erectile dysfunction. Urology (2000) 56:635-640.
40. YINGLU G: Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction in Chinese patients. 5th Asian Congress in Urology, Beijing, China (2000).
41. MCMAHON CG, SAMALI R, JOHNSON H: Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction. J. Urol. (2000) 164:1192-1196.
42. SADOVSKY R, MILLER T, MOSKOWITZ M et al.: Three-year update of sildenafil citrate (Viagra®) efficacy and safety. Int. J. Clin. Pract. (2001). 55:115-128.
43. ROSEN RC, RILEY A, WAGNER G et al.: The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology (1997) 49:822-830. This paper represents the first published report of the IIEF, a widely used validated-self assessment scale that investigates, not only ED but all the areas of male sexual life.
44. BOULTON AJM, SELAM JL, SWEENEY M et al.: Sildenafil citrate for the treatment of erectile dysfunction in men wiith Type II diabetes mellitus. Diabetologia (2001) 44:1296-1301.
45. CARSON CC, BURNETT AL, LEVINE LA et al: The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology (2002) 60(2, Suppl. 2):12-27.
46. GIULIANO F, MONTORSI F, MIRONE V et al.: Switching from intracavernous prostaglandin E1 injections to oral sildenafil citrate in patients with erectile dysfunction: results of a multicenter European study. J. Urol. (2000) 164:708-711.
47. HATZICHRISTOU DG, APOSTOLIDIS A, TZORTZIS V et al.: Sildenafil versus intracavernous injection therapy: efficacy and preference in patients on intracavernous injection for more than 1 year. J. Urol (2000) 164:1197-1200.
48. SAIRAM K, KULINSKAYA E, HANBURY D et al.: Oral sildenafil (Viagra™) in male erectile dysfunction: use, efficacy and safety profile in an unselected cohort presenting to a British district general hospital. BMC Urol. (2002) 2:4.
49. MOORE RA, EDWARDS JE, MCQUAY HJ: Sildenafil (Viagra™) for male erectile dysfunction: a meta-analysis of clinical trial reports. BMC Urol. (2002) 2:6.
50. FINK HA, MACDONALD R, RUTKS IR et al.: Sildenafil for male erectile dysfunction. A systematic review and meta-analysis. Arch. Intern. Med (2002) 162:1349-1360.
51. FAGELMAN E, FAGELMAN A, SHABSIGH R: Efficacy, safety, and use of sildenafil in urologic practice. Urology (2001) 57:1141-1144.
52. LEWIS R, BENNET CJ, BORKON WD et al.: Patient and parmer satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire. Urology (2001) 57:960-965.
53. ALTHOF SE, CORTY EW, LEVINE SB: Edits: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology (1999) 53:793-799.
54. PATTERSON B, BEDDING A, JEWELL H et al.: Dose-normalized pharmacokinetics of single dose-tadalafil (IC351) in healthy volunteers. Int. J. Impot. Res. (2001) 13(Suppl. 5):S62 (Abstract 14).
55. ANGULO J, GADAU M, FERNANDEZ A et al.: IC351 enhances NO-mediated relaxation of human arterial and trabecular penile smooth muscle. Eur. Urol. (2001) 39:106 (Abstract 415).
56. EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR): Summary of product characteristics: cialis. First published June 12, 2002.
57. PADMA-NATHAN H, ROSEN RC, SHABSIGH R et al.: Cialis (IC351) provides prompt response and extended period of responsiveness in the treatment of men with erectile dysfunction (ED). J. Urol. (2001) 165(Suppl.):A923.
58. PADMA-NATHAN H, MCMURRAY JG, PULLMAN WE et al.: On demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int. J. Impot. Res. (2001) 13:2-9.
59. PORST H: Daily IC351 treatment of ED. Int. J. Impot. Res. (2000) 12(Suppl. 3):S76, A-B13.
60. SAENZ DE TEJADA I, EMMICK J, ANGLIN G et al.: The effect of as-needed tadalafil (IC351) treatment of erectile dysfunction in men with diabetes. Int. J. Impot. Res. (2001) 13(Suppl. 4):A128.
61. ROSEN RC, CAPPELLERI JC, GENDRANO N 3rd: The International Index of Erectile Function (IIEF): a state-of-the-science review. Int. J. Impot. Res. (2002) 14:226-244.
62. MONTORSI F, MCCULLOUGH A, BROCK GB et al.: Tadalafil in the treatment of erectile dysfunction following bilateral nerve-sparing radical retropubic prostatectomy: a randomized, double-blind, placebo-controlled trial. J. Urol. (2004) (Submitted). This research underlines the efficacy and safety of tadalafil in a difficult to treat population represented by patients affected by localised prostate cancer who underweat nerve-sparing radical prostatectomy.
63. PATTERSON B, BEDDING A, JEWELL H et al.: The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351). Int. J. Impot. Res. (2001) 13(Suppl. 4):A120.
64. PORST H: IC351 (tadalafil, Cialis): update on clinical experience. Int. J. Impot. Res. (2002) 14(Suppl. 1):S57-S64.
65. KLONER RA, MITCHELL M, EMMICK JT: Cardiovascular effects of tadalafil in patients on common antihypertensive therapy. Am. J. Cardiology (2003) 92(Suppl. 1):47-57. As shown by this paper, tadalafil is provided with an excellent profile in terms of safety which was also found in patients affected by hypertension who were treated with oral therapy.
66. KLONER RA, HUTTER AM, EMMICK JT et al.: Time course of the interaction between tadalafil and nitrates. J. Am. Coll. Cardiol. (2003) 42:1855-1860.
67. HELLSTROM WJG, OVERSTREET JW, YU A et al.: Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J. Urol. (2003) 170:887-891. This research has clearly underlined the safety profile of tadalafil, in terms of spermatogenesis, as its potential interaction with PDE5-11, found in the testis, had previously raised questions about this issue.
68. STARK S, SACHSE R, LIEDL T et al.: Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur. Urol. (2001) 40:181-190.
69. KLOTZ T, SACHSE R, HEIDRICH A et al.: Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J. Urol. (2001) 19:32-39.
70. PORST H, ROSEN R, PADMA-NATHAN H et al.: The efficacy and tolerability of vardenafil, a new, oral selective PDE-5 inhibitor, in patients with erectile dysfunction: first at-home clinical trial. Int. J. Impot. Res. (2001) 13:192-199.
71. GOLDSTEIN I, YOUNG JM, FISCHER J et al.: Vardenafil, a new phosphodiesterase Type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care (2003) 26:777-783.
72. BROCK G, NEHRA A, LIPSHULTZ LI et al.: Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical prostatectomy. J. Urol. (2003) 170:1278-1283.
73. HELLSTROM WJ, GITTELMAN M, KARLIN G et al.: Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase Type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology. (2003) 61(4, Suppl. 1):8-14. This research underlines the efficacy and safety of vardenafil, in a difficult to treat population represented by patients affected by localised prostate cancer who underwent radical prostatectomy.
74. THADANI U, SMITH W, NASH S et al.: The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J. Am. Coll. Cardiol. (2002) 4(40):2006-2012.
75. PRYOR JP: Vardenafil: update on clinical experience. Int. J. Impot. Res. (2002) 14(Suppl. 1):S65-S69.
76. MELIS MR, ARGIOLAS A: Central oxytocinergic neurotransmission: a drug target for the therapy of psychogenic erectile dysfunction. Curr. Drug Targets (2003) 4:55-66.
77. ARGIOLAS A, MELIS MR: Neuromodulation of penile erection: an overview of the role of neurotransmitters and neuropeptides. Progr. Neurobiol. (1995) 47:235-255.
78. MIRONE VG, STIEF CG: Efficacy of apomorphine SL in erectile dysfunction. BJU Int. (2001) 88(Suppl. 3):25-29.
79. DULA E, BUKOFZER S, PERDOK R et al.: Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur. Urol. (2001) 39:558-564.
80. HEATON JP, DEAN J, SLEEP DJ: Sequential administration enhances the effect of apomorphine in men with erectile dysfunction. Int. J. Impot. Res. (2002) 14:61-64.
81. MONTORSI F: Tolerability and safety of apomorphine SL (Ixense (TM)). Int. J. Impot. Res. (2003) 15(Suppl. 2):S7-S9.
82. BUVAT J, MONTORSI F: Safety and tolerability of apomorphine SL in patients with erectile dysfunction. BJU Int. (2001) 88(Suppl. 3):30-35.
83. PERIMENIS P, GYFTOPOULOS K, GIANNITSAS K et al.: A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction. Int. J. Impot. Res. (2004) 16:2-7.